There are currently 61 active clinical trials seeking participants for Ulcerative Colitis research studies. The states with the highest number of trials for Ulcerative Colitis participants are Florida, California, Texas and New York.
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
NCT03847467
Recruiting
Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in IBD will be safe and well tolerated, while increasing fecal Bifidobacterium abundance and butyrate in a dose dependent manner. The investigators will test 1, 5, or 10 gm 2'-FL compared to 2 gm dextrose placebo as a daily dietary supplement in pediatric and young adult IBD participants in stable remission receiving inflixi... Read More
Gender:
ALL
Ages:
Between 11 years and 25 years
Trial Updated:
06/11/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut +2 locations
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Register for Updates
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950
Recruiting
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study,... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2025
Locations: GastroIntestinal BioSciences, Los Angeles, California +175 locations
Conditions: Ulcerative Colitis
Register for Updates
Treatment of UC With Novel Therapeutics
NCT06420375
Recruiting
This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with active mild ulcerative colitis. Participation in this study will take 12 weeks long and the study is structured as a crossover study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study will require participa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2025
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Ulcerative Colitis Mild, Ulcerative Colitis
Register for Updates
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615
Recruiting
Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension of the parent studies, TAK-279-CD-2001 (NCT06233461) and TAK-279-UC-2001 (NCT06254950). This means that participants who responded to treatment with TAK-279 in either of the parent studies may be able... Read More
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
06/03/2025
Locations: Tyler Research Institute, LLC, Tyler, Texas
Conditions: Crohn's Disease, Ulcerative Colitis
Register for Updates
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/03/2025
Locations: Om Research, Lancaster, California +36 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
NCT06109441
Recruiting
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, a Maintenance Phase, and an OLE.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2025
Locations: San Diego Gastroenterology, San Diego, California +23 locations
Conditions: Ulcerative Colitis
Register for Updates
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
NCT06315179
Recruiting
This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut inflammation.
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
05/14/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis, Functional Abdominal Pain Syndrome, Functional Bowel Disorder, Esophageal Diseases, Gastroduodenal Disorder, Bowel Dysfunction, Gallbladder Diseases, Sphincter of Oddi Dysfunction, Anorectal Disorder
Register for Updates
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
NCT04751396
Recruiting
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis, Enteropathic Arthritis, Enteropathic Spondylitis
Register for Updates
Nicotinamide Riboside in Ulcerative Colitis
NCT05561738
Recruiting
This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/05/2025
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Ulcerative Colitis
Register for Updates
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
NCT06750731
Recruiting
The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis, and inflammatory bowel disease type undetermined) initiating therapy with vedolizumab (Entvyio). The main questions it aims to answer are: 1. Assess and compare adherence to intravenous (IV) and subcutaneous vedolizumab maintena... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Tulane University, New Orleans, Louisiana +5 locations
Conditions: Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
Register for Updates
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Arizona Digestive Health, Sun City, Arizona +122 locations
Conditions: Ulcerative Colitis
Register for Updates
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
NCT06424769
Recruiting
The goal of this clinical trial is to learn whether IBD patients have better disease outcomes and feel more empowered to manage their condition if they have access to text messaging with their clinical team and if their symptoms are more regularly monitored through text-based surveys. Researchers will compare participants who have access to text-based monitoring, communication and education to participants who have access to text-based education alone. Researchers will also examine if different... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
05/01/2025
Locations: University of California San Diego, San Diego, California +7 locations
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colitis
Register for Updates